Discovering and developing a new class of drugs that work by modulating the protein regulation machinery of the cell
Nurix, Inc. is a leader in the discovery of small molecules that modulate the ubiquitin proteasome system (UPS) to address significant, unmet medical needs. The UPS is a regulatory pathway that controls protein levels, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas. Nurix was founded by internationally recognized experts in the ubiquitin proteasome field.
Year Invested: 2013
Location: San Francisco, Calif.